Cyclerion Therapeutics, Inc. (CYCN) Revenue History
Annual and quarterly revenue from 2017 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CYCN Revenue Growth
Revenue Breakdown (FY 2024)
CYCN's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
CYCN Revenue Analysis (2017–2025)
As of May 7, 2026, Cyclerion Therapeutics, Inc. (CYCN) generated trailing twelve-month (TTM) revenue of $2.1 million, reflecting significant decline in growth of -43.2% year-over-year. The most recent quarter (Q4 2025) recorded $1.0 million in revenue, up 17.1% sequentially.
Looking at the longer-term picture, CYCN's 5-year compound annual growth rate (CAGR) stands at -2.0%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $4.5 million in 2019.
Revenue diversification analysis shows CYCN's business is primarily driven by License Agreement (88%), and License (13%). With over half of revenue concentrated in License Agreement, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ADMA (+19.6% YoY), PRTA (-92.8% YoY), and MNKD (+21.2% YoY), CYCN has underperformed the peer group in terms of revenue growth. Compare CYCN vs ADMA →
CYCN Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CYCNCurrent | $2M | -43.2% | -2.0% | -239.8% | |
 ADMA | $510M | +19.6% | +64.6% | 37.5% | |
 PRTA | $10M | -92.8% | +62.6% | -1905.8% | |
 MNKD | $349M | +21.2% | +39.9% | 11.1% |
CYCN Historical Revenue Data (2017–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.1M | +3.7% | $2.1M | 100.0% | $-4,973,000 | -239.8% |
| 2024 | $2.0M | - | $2.0M | 100.0% | $-3,628,000 | -181.4% |
| 2023 | $0 | -100.0% | $0 | - | $-12,951,000 | - |
| 2022 | $297K | -91.1% | $-5,282,000 | -1778.5% | $-18,540,000 | -6242.4% |
| 2021 | $3.3M | +44.6% | $3.3M | 100.0% | $-55,195,000 | -1662.5% |
| 2020 | $2.3M | -49.1% | $-54,118,000 | -2357.1% | $-81,265,000 | -3539.4% |
| 2019 | $4.5M | - | $-90,633,000 | -2010.9% | $-125,037,000 | -2774.3% |
| 2018 | $0 | - | $-1,528,000 | - | $-115,252,000 | - |
| 2017 | $0 | - | $-1,745,000 | - | $-93,922,000 | - |
See CYCN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CYCN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CYCN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCYCN — Frequently Asked Questions
Quick answers to the most common questions about buying CYCN stock.
Is CYCN's revenue growth accelerating or slowing?
CYCN revenue declined -43.2% year-over-year, contrasting with the 5-year CAGR of -2.0%. TTM revenue fell to $2M. This reverses the prior growth trend.
What is CYCN's long-term revenue growth rate?
Cyclerion Therapeutics, Inc.'s 5-year revenue CAGR of -2.0% reflects the variable expansion pattern. Current YoY growth of -43.2% is below this long-term average.
How is CYCN's revenue distributed by segment?
CYCN reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2017-2025 are available for download. Segment mix reveals concentration and diversification trends.